BioNTech's fourth-quarter performance fell short of expectations, with the stock plunging over 19%

Germany Mainz - On Tuesday, BioNTech SE (NASDAQ:BNTX) announced its Q4 earnings, showing that despite revenue exceeding expectations, earnings per share fell short of analyst forecasts.

Following the announcement, the company’s stock dropped 19.68% in pre-market trading.

The German biotech company’s adjusted Q4 loss was $0.33 per share, compared to the analyst consensus loss of $0.19.

Revenue was €907.4 million ($907.2 million), surpassing the analyst estimate of $758.8 million, but down 24% year-over-year from €1.19 billion in Q4 2024.

The revenue decline was mainly due to reduced market demand leading to a drop in COVID-19 vaccine sales.

For the full fiscal year 2025, BioNTech reported revenue of €2.9 billion, a 4% increase from €2.8 billion in 2024. The adjusted net loss was €117.1 million ($0.48 per share), compared to an adjusted net profit of €121.7 million ($0.50 per share) in 2024.

“2025 has been a year of strong execution and significant progress in our R&D pipeline, marking substantial advances toward our strategic goals,” said BioNTech CEO and co-founder Professor Ugur Sahin.

The company issued guidance for 2026, expecting total revenue between €2 billion and €2.3 billion, with a midpoint of €2.15 billion, indicating continued pressure from declining COVID-19 vaccine demand.

BioNTech projects adjusted R&D expenses of €2.2 billion to €2.5 billion, and adjusted SG&A expenses of €700 million to €800 million.

BioNTech announced that co-founders Ugur Sahin and Özlem Türeci will establish an independent company focused on next-generation mRNA innovation, with both transitioning to the new company by the end of 2026.

As of December 31, 2025, the company maintained a strong financial position, with cash, cash equivalents, and securities investments totaling €17.2 billion.

This article was translated with AI assistance. For more information, see our Terms of Use.